In recent years, the use of dosimetry to support radionuclide therapy has gained importance as documented by the increased number of articles addressing dosimetry. e latest literature reports some remarkable correlations between absorbed dose delivered, response, and toxicity, which have advanced the understanding of radiobiological eects. In a recent review published by Strigari et al. (2011), dose-eect relationships were collected and these indicated that dosimetry-based personalized treatments would improve outcomes and increase survival and open the way toward predictivity and personalization of therapy. Available evidence covers nearly all widely used nuclear medicine therapies, including
the treatment of dierentiated thyroid cancer and benign thyroid disease with 131I, neuroblastomas with 131I-mIBG (metaiodobenzylguanidine), neuroendocrine tumors with 177Lu and 90Y radiopeptides, bone pain palliation with 153Sm-ethylene diamine tetramethylene phosphonate (153Sm-EDTM), and also radioembolization of primary and secondary liver cancer with 90Y-microspheres.